Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA‐B) genotype and allopurinol dosing: 2015 update
Year: 2015
Type: article
Abstract: The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).
DOI: 10.1002/cpt.161
Institutions: National Institute of Health Sciences, University of Otago, St. Jude Children's Research Hospital, Duke University, Duke Medical Center, Stanford Medicine, Veterans Health Administration, Indiana University Indianapolis, Indiana University School of Medicine, Khon Kaen University, RIKEN, StaGen (Japan), National Institutes of Health, National Institutes of Health Clinical Center, Murdoch University, Vanderbilt University Medical Center, China Medical University, Institute of Biomedical Sciences, Academia Sinica, RIKEN Center for Integrative Medical Sciences, Academia Sinica
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: PAAR4Kids-Pharmacogenomics of Anticancer Agents Research in Children, Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) Study, G2075386466, Clinical Pharmacogenetics Implementation Consortium (CPIC), PharmGKB: pharmacogenomics knowledge for precision medicine, G3749375069, G6734486794, G6975866337, G9000203062
OpenAlex ID: W1817590545